Abstracts tagged "Sjogren’s syndrome"

Abstract Number: 2430 • 2019 ACR/ARP Annual Meeting
Detection and Clinical Significance of Circulating M3 Muscarinic Acetylcholine Receptor Reactive Th17 Cells in Patients with Primary Sjögren’s Syndrome
Saori Abe¹, Hiroto Tsuboi ¹, Yuko Ono ², Fumika Honda ¹, Mizuki Yagishita ¹, Izumi Kurata ¹, Ayako Ohyama ¹, Hiroyuki Takahashi ¹, Yuya Kondo ¹, Isao Matsumoto ¹ and Takayuki Sumida ¹, ¹Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Section of Oral and Maxillofacial Oncology, Division of Maxillofacial Diagnostic and Surgical Science, Faculty of Dental Science, Kyushu University, Tsukuba, Japan
Background/Purpose: Sjögren’s syndrome (SS) is an autoimmune disease which is characterized by lymphocytic infiltration including CD4+ IL-17 producing helper T (Th17) cells to the lacrimal and…
Abstract Number: 1451 • 2019 ACR/ARP Annual Meeting
Histological Characteristics in SICCA Syndrome – Clinical and Serological Association
Maria de Lourdes Flores ¹, Gabriela Alejandra Gutierrez-Robles ¹, Flavio Cesar Estrada-Gil ¹, Miguel Alejandro Davalos-Benitez ¹, Jorge Ernesto Garcia-Alvarado ¹, Alejandra de Lourdes Farias-Sierra¹, Ignacio Garcia-De La Torre ², Gerardo Orozco-Barocio ¹, Carlos Gerardo Riebeling-Navarro ³ and Arnulfo Hernan Nava-Zavala ⁴, ¹HGO SSJ, U de G, PNPC CONACYT, Guadalajara, Mexico, ²Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Jalisco, Mexico, ³UIEC UMAE HP CMN-SXXI IMSS / UNAM, Ciudad de Mexico, Mexico, ⁴UIB02 UMAE HE CMNO IMSS / HGO SSJ / PIM UAG / PNPC U de G, Guadalajara, Mexico
Background/Purpose: The xerostomia and/or xerophtalmia (SICCA syndrome: items I and II of 2002 AECG criteria) are conspicuous characteristics of primary Sjögren´s syndrome (pSS). pSS diagnostic…
Abstract Number: 1906 • 2019 ACR/ARP Annual Meeting
Using Multi-modal Ultrasound to Assess Disease Activity Within the Salivary Glands of Patients with Primary Sjögren’s Syndrome Treated with Ianalumab (VAY736)
Torsten Diekhoff ¹, Maximilian Posch ², Frank Wagner ², Thomas Fischer ¹, Quirino Schefer ², Thomas Dörner ³, Didier Laurent ⁴, Yue Li ⁴ and Stephen Oliver⁴, ¹Charité University Hospital, Berlin, Germany, ²Charité Research Organisation, Berlin, Germany, ³Charite Universitätsmedizin Berlin and DRFZ, Berlin, Germany, ⁴Novartis Pharma AG, Basel, Switzerland
Background/Purpose: To use ultrasound (US) to demonstrate that ianalumab, a monoclonal antibody with dual mechanisms-of-action of BAFF:BAFF-R blockade and enhanced, ADCC-mediated B cell depletion, can…
Abstract Number: 2431 • 2019 ACR/ARP Annual Meeting
Extracellular Vesicles in Primary Sjögren’s Syndrome: A Promising Source for Novel Proteomic Biomarkers
Chiara Baldini¹, Francesco Finamore ², Francesco Ferro ¹, Silvia Rocchiccioli ², Marta Mosca ³, Letizia Mattii ⁴ and Antonella Cecchettini ⁴, ¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, Pisa, Italy, ²National Research Council – Clinical Institute of Physiology, PISA, Italy, ³Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Italy, ⁴University of Pisa, Pisa, Italy
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a complex autoimmune disorder characterized by the specific involvement of salivary and lachrymal glands. In the recent past several…
Abstract Number: 1452 • 2019 ACR/ARP Annual Meeting
Comparison of Clinical Phenotype, Serological Characteristics and Histologic Features Between Males and Females Patients with Primary Sjögren’s Syndrome (pSS)
Loukas Chatzis¹, Saviana Gandolfo ², Francesco Ferro ³, Marco Binutti ², Valentina Donati ⁴, Sara Zandonella Callegher ⁵, Vasilis Pezoulas ⁶, Aliki Venetsanopoulou ⁷, Argyropoulou Ourania ⁷, Georgios Michalopoulos ⁷, maria pappa ⁷, Clio Mavragani ⁷, Dimitris fotiadis ⁸, Chiara Baldini ³, Salvatore De Vita ², Athanasios Tzioufas ¹ and Andreas Goules ⁷, ¹Department of Pathophysiology, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ²Rheumatology Clinic, Udine University Hospital, Department of Medical Area, University of Udine, Udine, Italy, Udine, Italy, ³Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, Pisa, Italy, ⁴University of Pisa, Pisa, ⁵Rheumatology Clinic, Udine University Hospital, Udine, Italy, Udine, Italy, ⁶Unit of Medical Technology and Intelligent Information Systems, University of Ioannina, GR45110, Ioannina, Greece, Ioannina, Greece, ⁷Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁸Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Ioannina, Greece
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a female predominant autoimmune disease and very few studies have been conducted to investigate the phenotypic differences of the…
Abstract Number: 2413 • 2019 ACR/ARP Annual Meeting
LOU064: A Highly Selective and Potent Covalent Oral BTK Inhibitor with Promising Pharmacodynamic Efficacy on B Cells for Sjoegren’s Syndrome
Bruno Cenni¹, Peter End ¹, Maciej Cabanski ¹, Annamaria Jakab ¹, Enrico Funhoff ¹, Magdalena Kistowska ¹, Arvind Kinhikar ², Alessio Maiolica ¹, Masaru Hirano ³, Barbara Nuesslein-Hildesheim ¹, Amanda Littlewood-Evans ¹, Daniela Angst ¹, Robert Pulz ⁴ and Martin Kaul ¹, ¹Novartis Institutes for BioMedical Research, Basel, Switzerland, ²Novartis Institutes for BioMedical Research, Cambridge, MA, ³Novartis Institutes for BioMedical Research, Tokyo, Japan, ⁴Novartis Institues for BioMedical Research, Basel, Switzerland
Background/Purpose: Bruton’s Tyrosine Kinase (BTK) is a cytoplasmic tyrosine kinase selectively expressed in B cells, macrophages, mast cells and basophils. The essential role of BTK…
Abstract Number: 2432 • 2019 ACR/ARP Annual Meeting
Thymic Stromal Lymphopoietin (TSLP) as a Biomarker of Primary Sjögren’s Syndrome (pSS) and Related Lymphoma: Results in Independent Cohorts
Saviana Gandolfo¹, Cinzia Fabro ¹, Serena Colafrancesco ², Francesco Carubbi ³, Francesco Ferro ⁴, Elena Bartoloni ⁵, Efstathia Kapsogeorgou ⁶, Andreas Goules ⁶, Luca Quartuccio ¹, Roberta Priori ², Alessia Alunno ⁵, Guido Valesini ², Roberto Giacomelli ³, Roberto Gerli ⁵, Chiara Baldini ⁴, Athanasios Tzioufas ⁶ and Salvatore De Vita ¹, ¹Rheumatology Clinic, Udine University Hospital, Department of Medical Area, University of Udine, Udine, Italy, Udine, Italy, ²Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, Roma, Italy, ³Rheumatology Unit, Department of Biotechnological and Applied Clinical Science, School of Medicine, University of L'Aquila, L'Aquila, Italy, L'Aquila, Italy, ⁴Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, Pisa, Italy, ⁵Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, Italy, Perugia, Italy, ⁶Department of Pathophysiology, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece
Background/Purpose: Thymic stromal lymphopoietin (TSLP) has been implicated in primary Sjögren’s syndrome (pSS) and related B-cell lymphoproliferation / lymphoma (NHL) by tissue studies on salivary…
Abstract Number: 1453 • 2019 ACR/ARP Annual Meeting
Baseline EULAR Sjögren’s Syndrome Patient-Reported Index Has a Significant Impact on the Longitudinal Course of Sjögren’s Syndrome
Eun Hye Park¹, You-Jung Ha ¹, Eun Ha Kang ¹, Yeong-Wook Song ² and Yun Jong Lee ³, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, ²Seoul National University Hospital, Seoul, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea
Background/Purpose: The EULAR Sjögren's syndrome (SS) disease activity index (ESSDAI) and EULAR SS Patient-Reported Index (ESSPRI) have been validated as disease activity and outcome measures…
Abstract Number: 2414 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Abatacept in Patients with Early Active Primary Sjögren’s Syndrome – Open-label Extension Phase of a Randomized Controlled Phase III Trial
Jolien van Nimwegen¹, Esther Mossel ¹, Robin Wijnsma ¹, Greetje van Zuiden ¹, Konstantina Delli ¹, Alja Stel ¹, Bert van der vegt ¹, Erlin Haacke ¹, Lisette Olie ¹, Leonie Los ¹, Gwenny Verstappen ¹, Sarah Pringle ¹, Fred Spijkervet ¹, Frans Kroese ¹, Arjan Vissink ¹, Suzanne Arends ² and Hendrika Bootsma ³, ¹University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Dept. of Rheumatology and Clinical Immunology - University Medical Center Groningen (UMCG), University of Groningen, Groningen, Netherlands, ³University of Groningen, Groningen, Netherlands
Background/Purpose: Abatacept (CTLA-4-Ig) targets the CD80/CD86:CD28 co-stimulatory pathway required for full T-cell activation and T-cell dependent activation of B-cells. The Abatacept Sjögren Active Patients phase…
Abstract Number: 2433 • 2019 ACR/ARP Annual Meeting
Fatigue in Primary Sjögren’s Syndrome as a Manifestation of Heavier Disease Activity of Mucosa-Associated Lymphoid Tissue (MALT)
Saviana Gandolfo¹, Marco Binutti ¹, Elena Doriguzzi Breatta ¹, Cinzia Fabro ¹ and Salvatore De Vita ¹, ¹Rheumatology Clinic, Udine University Hospital, Department of Medical Area, University of Udine, Udine, Italy, Udine, Italy
Background/Purpose: Fatigue is one of the most prevalent and impacting symptoms in primary Sjögren’s syndrome (pSS), significantly impairing the patient quality of life. To date,…
Abstract Number: 1454 • 2019 ACR/ARP Annual Meeting
Sjӧgren’s Syndrome Foundation National Survey: The Impact and Burden of Oral Symptoms
Sara McCoy¹, Christie Bartels ², Esen Akpek ³, Ian Saldanha ⁴, Vatinee Bunya ⁵, Matthew Makara ⁶ and Alan Baer ⁷, ¹University of Wisconsin School of Medicine and Public Health, Madison, ²University of Wisconsin School of Medicine and Public Health, Madison, WI, ³Johns Hopkins University, Baltimore, ⁴Brown University School of Public Health, Providence, RI, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Sjogren's Syndrome Foundation, Reston, VA, ⁷Johns Hopkins University, Baltimore, MD
Background/Purpose: Sjӧgren’s syndrome (SS) is the second most common systemic autoimmune disease, typically characterized by ocular and oral sicca. SS is associated with reduced quality…
Abstract Number: 2415 • 2019 ACR/ARP Annual Meeting
Evaluation of Pharmacokinetics and Immunogenicity Following Subcutaneous Administration of Abatacept in Primary Sjogren ’s Syndrome (pSS) and RA Patients
Yash Gandhi¹, Mehmooda Shaikh ², Blisse Vakkalagadda ¹, Grigor Abelian ¹, Neelanjana Ray ¹, Robert Wong ¹ and Bindu Murthy ¹, ¹Bristol-Myers Squibb, Princeton, ²Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Abatacept (ABA) has proven efficacy in autoimmune diseases and is being evaluated in pSS. The purpose of this investigation was to evaluate the pharmacokinetics…
Abstract Number: 2434 • 2019 ACR/ARP Annual Meeting
Risk of Lymphoma and Thyroid Cancer in Primary Sjögren’s Syndrome Measured Using the Korean Health Insurance Claims Database
Joong Kyong Ahn ¹, Jiwon Hwang² and Gi Hyeon Seo ³, ¹Division of Rheumatology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon-si, Republic of Korea, ³Health Insurance Review and Assessment Service, Wonju, Republic of Korea
Background/Purpose: The development of lymphomas is one of the most serious complications of SjS but the incidence, prevalence and estimated risk of lymphoma in primary…
Abstract Number: 1455 • 2019 ACR/ARP Annual Meeting
B and T Cell Immunologic Features Associated with Higher Disease Activity Score and Focus Score in Primary Sjögren Syndrome
Alice Mai¹, Yuriy Baglaenko ², Dario Ferri ³, Kieran Manion ⁴, Dennisse Bonilla ⁵, Arthur Bookman ⁶ and Joan Wither ⁷, ¹University of British Columbia Department of Rheumatology, Vancouver, Canada, ²Brigham Woman's Hospital, Boston, ³University Health Network, Toronto, ON, Canada, ⁴Krembil Research Institute, Toronto, ON, Canada, ⁵University Health Network, University of Toronto, Toronto, ON, Canada, ⁶University Health Network, Toronto, Canada, ⁷University Health Network, Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: Primary Sjögren syndrome (pSS) is a systemic autoimmune disease with an incompletely understood pathogenesis and heterogenous disease manifestations. Identifying cellular immune changes that may…
Abstract Number: 2416 • 2019 ACR/ARP Annual Meeting
ALPN-101, a First-in-Class Dual ICOS/CD28 Antagonist, Suppresses Key Effector Mechanisms Associated with Sjögren’s Syndrome
Stacey Dillon¹, Lawrence Evans ¹, Katherine Lewis ¹, Susan Bort ¹, Erika Rickel ¹, Jing Yang ¹, Martin Wolfson ¹, Kayla Susmilch ¹, Sherri Mudri ¹, Steven Levin ¹, Janhavi Bhandari ¹, Fariha Ahmed-Qadri ¹, Mark Rixon ¹, Jan Hillson ², Stanford Peng ¹ and Kristine Swiderek ¹, ¹Alpine Immune Sciences, Seattle, WA, ²Alpine Immune Sciences, Seattle, WI
Background/Purpose: ALPN-101 is an Fc fusion protein of a human inducible T cell costimulator ligand (ICOSL) variant immunoglobulin domain (vIgDTM) designed to inhibit simultaneously the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].